A Study to Assess Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in Participants With Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer

NCT01565083 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

213

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Pertuzumab
DRUG: Trastuzumab
DRUG: Vinorelbine

Sponsor

Hoffmann-La Roche